GlassScriptPhysician profile
Jean C Emond
NPI 1487606307
$1,738.90
in general payments reported to CMS, 2019-2025
11 companies · $644 in 2025
The $644 reported for 2025 was more than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.30 · 2023: $321 · 2024: $696 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $517.07 | 2024-2025 | |
| Fujifilm Healthcare Americas Corporation | $284.60 | 2024 | Synapse 3d, Arietta Precision |
| Intuitive Surgical, INC. | $278.50 | 2024-2025 | |
| Organox LTD | $171.76 | 2025 | |
| Ethicon US, LLC | $170.61 | 2023-2024 | Echelon; Endopath, Prolene, Surgicel Nu-Knit |
| Olympus America INC. | $154.47 | 2023 | Visera Elite II Video System Center Olympus Otv-S300, Olympus |
| Regeneron Pharmaceuticals, INC. | $77.30 | 2019 | |
| Mirum Pharmaceuticals, INC. | $22.24 | 2023 | Livmarli |
| Boston Scientific Corporation | $21.50 | 2024 | Spyglass Discover |
| Astrazeneca Pharmaceuticals LP | $20.72 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.13 | 2023 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Emond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.